IL2 (Interleukin-2) is a foundational T cell cytokine discovered in 1976 and is one of the most important cytokines for immune regulation. IL-2 is critical for T cell proliferation, survival, and differentiation, and plays central roles in immune tolerance, autoimmunity, and cancer immunity. In the nervous system, IL-2 influences neurodevelopment, synaptic plasticity, and has complex roles in neuroinflammation and neurodegenerative diseases.
|
|
| Symbol |
IL2 |
| NCBI Gene ID |
3559 |
| Chromosome |
4q26 |
| Protein Class |
Cytokine |
| Molecular Weight |
~15 kDa |
IL-2 has essential and complex functions:
- T cell proliferation: Primary cytokine driving activated T cell expansion
- Treg development: Essential for regulatory T cell (Treg) maintenance and function
- NK cell activation: Enhances NK cell cytotoxicity and proliferation
- Immune tolerance: Central to self-tolerance via Treg maintenance
- Neurodevelopment: Influences neural precursor cell proliferation and differentiation
- Synaptic plasticity: IL-2 receptor expression in hippocampus suggests roles in learning and memory
- Neuroinflammation: Modulates CNS inflammatory responses
- Neuroprotective potential: Some studies suggest neuroprotective effects
IL-2 signals through three receptor configurations:
- Low-affinity: IL2Rα (CD25) alone - not signaling competent
- Intermediate-affinity: IL2Rβγ (CD122/CD132) - on NK cells and memory T cells
- High-affinity: IL2Rαβγ (CD25/CD122/CD132) - on activated T cells and Tregs
The expression of different receptor forms determines cellular responses.
IL-2 activates multiple signaling cascades:
- JAK/STAT pathway: JAK1/JAK3 and primarily STAT5
- PI3K/Akt pathway: Critical for cell survival and metabolic signaling
- MAPK/ERK pathway: Cell proliferation and differentiation
- PLC-γ pathway: Calcium signaling
- Alzheimer's Disease: IL-2 levels altered in AD; potential therapeutic candidate; some clinical trials of IL-2 in AD
- Parkinson's Disease: IL-2 may modulate neuroinflammation; dopaminergic neuron survival
- Multiple Sclerosis: IL-2 drives T cell activation; IL-2 therapy being explored
- ALS: Altered IL-2 signaling in ALS models
- Cancer immunotherapy: IL-2 (aldesleukin) approved for melanoma and renal cell carcinoma
- Autoimmune diseases: Low-dose IL-2 for treating lupus, vasculitis
- HIV/AIDS: IL-2 used in some clinical trials
- Transplant rejection
IL-2 is produced primarily by activated immune cells:
| Cell Type |
Expression Level |
Notes |
| Activated CD4+ T cells |
High |
Primary source |
| Activated CD8+ T cells |
High |
Autocrine signaling |
| NK cells |
Moderate |
Early response |
| Neurons |
Low |
Constitutive |
| Astrocytes |
Low |
Inducible |
IL-2 has significant clinical applications:
- Aldesleukin (Proleukin): FDA-approved for metastatic renal cell carcinoma and melanoma
- Low-dose IL-2: Investigated for autoimmune diseases
- IL-2 muteins: Engineered IL-2 variants with altered receptor binding
- IL-2/IL-2 antibody complexes: Enhance therapeutic window
- Combination therapy: With checkpoint inhibitors in cancer